Ratings by Truist Securities (Nicole Germino)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/31/2025 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 8/14/2025 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 8/8/2025 | Insmed | INSM | Maintain | (N/A) |
|
Details | ||
| 8/5/2025 | Y-mAbs Therapeutics | YMAB | Downgrade | Hold (Buy) |
4.19 (8.61) |
105.49% | Details | |
| 6/10/2025 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 5/14/2025 | Y-mAbs Therapeutics | YMAB | Maintain | Buy (N/A) |
|
Details | ||
| 5/14/2025 | Perspective Therapeutics Inc | CATX | Maintain | Buy (N/A) |
|
Details | ||
| 4/7/2025 | Perspective Therapeutics Inc | CATX | Maintain | Buy (N/A) |
|
Details | ||
| 3/19/2025 | Sangamo BioSciences | SGMO | Maintain | Buy (N/A) |
|
Details | ||
| 3/11/2025 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 3/5/2025 | Y-mAbs Therapeutics | YMAB | Maintain | Buy (N/A) |
|
Details | ||
| 2/21/2025 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 1/23/2025 | Sangamo BioSciences | SGMO | Maintain | Buy (N/A) |
|
Details | ||
| 1/21/2025 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 1/13/2025 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 12/13/2024 | Sangamo BioSciences | SGMO | Upgrade | Buy (Hold) |
1.91 (0.38) |
-80.1% | Details | |
| 11/1/2024 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 10/11/2024 | Perspective Therapeutics Inc | CATX | Maintain | Buy (N/A) |
|
Details | ||
| 10/10/2024 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 9/25/2024 | Perspective Therapeutics Inc | CATX | New Coverage | Buy (N/A) |
12.28 (4.97) |
-59.53% | Details | |
| 8/12/2024 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 7/1/2024 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 6/28/2024 | Y-mAbs Therapeutics | YMAB | New Coverage | Buy (N/A) |
12.33 (4.19) |
-66.02% | Details | |
| 5/29/2024 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 4/23/2024 | Insmed | INSM | New Coverage | Buy (N/A) |
24.11 (198.46) |
723.14% | Details | |
| 3/19/2024 | Fusion Pharmaceuticals | FUSN | Downgrade | Hold (Buy) |
10.64 (21.55) |
102.54% | Details | |
| 11/7/2023 | Sangamo BioSciences | SGMO | Downgrade | Hold (Buy) |
0.44 (0.38) |
-13.64% | Details | |
| 10/3/2023 | POINT Biopharma Global Inc. | PNT | Downgrade | Hold (Buy) |
6.68 (12.50) |
87.13% | Details | |
| 8/15/2023 | Sangamo BioSciences | SGMO | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2023 | Sangamo BioSciences | SGMO | Maintain | Buy (N/A) |
|
Details | ||
| 3/1/2023 | Sangamo BioSciences | SGMO | Maintain | Buy (N/A) |
|
Details | ||
| 2/24/2023 | POINT Biopharma Global Inc. | PNT | Maintain | Buy (N/A) |
|
Details | ||
| 2/14/2023 | Fusion Pharmaceuticals | FUSN | Maintain | Buy (N/A) |
|
Details | ||
| 11/15/2022 | POINT Biopharma Global Inc. | PNT | Maintain | Buy (N/A) |
|
Details | ||
| 10/24/2022 | Assembly Biosciences | ASMB | Downgrade | Hold (Buy) |
1.54 (28.27) |
1735.71% | Details | |
| 9/16/2022 | Fusion Pharmaceuticals | FUSN | New Coverage | Buy (N/A) |
3.56 (21.55) |
505.34% | Details | |
| 9/16/2022 | POINT Biopharma Global Inc. | PNT | New Coverage | Buy (N/A) |
8.92 (6.68) |
-25.11% | Details | |
| 8/8/2022 | Sangamo BioSciences | SGMO | Maintain | Buy (N/A) |
|
Details | ||
| 6/8/2022 | Assembly Biosciences | ASMB | Maintain | Buy (N/A) |
|
Details | ||
| 4/4/2022 | Sangamo BioSciences | SGMO | Maintain | Buy (N/A) |
|
Details | ||
| 4/1/2022 | Assembly Biosciences | ASMB | Maintain | Buy (N/A) |
|
Details | ||
| 9/3/2021 | Forte Biosciences Inc. | FBRX | Downgrade | Hold (Buy) |
29.92 (28.76) |
-3.88% | Details | |
| 3/2/2021 | Assembly Biosciences | ASMB | Maintain | Buy (N/A) |
|
Details | ||
| 11/6/2020 | Assembly Biosciences | ASMB | Maintain | Buy (N/A) |
|
Details | ||
| 10/19/2020 | Assembly Biosciences | ASMB | New Coverage | Buy (N/A) |
15.62 (28.27) |
80.99% | Details | |
| 8/25/2020 | Forte Biosciences Inc. | FBRX | New Coverage | Buy (N/A) |
24.70 (28.76) |
16.44% | Details | |
| 8/20/2020 | Sangamo BioSciences | SGMO | Maintain | Buy (N/A) |
|
Details | ||
| 8/19/2020 | Sangamo BioSciences | SGMO | Maintain | Buy (N/A) |
|
Details |
